Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product.
In a notice posted on the Federal Register Wednesday, the FDA said that its Center for Drug Evaluation and Research (CDER) has proposed withdrawing the approval for Salerno’s FloLipid, an oral suspension formulation of the long-approved cholesterol-lowering medication simvastatin.
The FDA is taking action after Salerno allegedly “repeatedly failed to file annual reports” on the drug, which online sources indicate was approved by the FDA in 2016. Companies that hold an new drug approval must submit those reports to the FDA each year, but Salerno has failed to comply and further, the company “has not responded to the Agency’s request for submission of the reports,” per the Federal Register notice.
As part of the regulatory process that will now play out, Salerno has until Dec. 18 to request a hearing with the FDA to defend its medicine’s green light. If Salerno goes that route, it will then have until Jan. 19 to submit all data, analyses and written comments on FloLipid for the meeting.
The FDA’s proposal would account for both the 20 mg/5 mL and 40 mg/5mL doses of Salerno’s product. On a September list of FDA-approved medicines, FloLipid was the only product included (PDF) under Salerno’s name.
Salerno did not immediately respond to Fierce Pharma’s request for comment on the situation. On its website, the company does not appear to list traditional press releases, and it lists just two operating board members—and no executives—under a “Meet The Team” heading.
A short intro of the firm describes Salerno as a healthcare company that works to improve and optimize traditional pharmaceuticals, with a particular focus on more convenient routes of administration.
The product page for FloLipid, meanwhile, boasts its positioning as the U.S.’ first liquid medicine approved to lower cholesterol, noting that the drug was formulated to appeal to patients who have difficulty swallowing pills. Originally developed by Merck & Co., simvastatin first won approval under the brand name Zocor back in the 1990s before making its way over to Organon during that company’s spinout from Merck in 2021.
Reformulating approved therapies for easier administration—and in some cases novel indications—has become an increasingly popular strategy for specialty drugmakers in recent years.
The approach underpins efforts from commercial-stage companies ike Taiwan’s Handa Pharmaceuticals, as well as a growing slate of developers looking to home in on easier dosing for time-tested drugs for conditions like hair loss and male contraception.